Chiropractors in Magee, MS Accepting Medicare
3 Chiropractors found. Showing 1 - 3
 Performance Chiropractic And Rehab, P.c. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 448 5th Ave Sw, Magee, MS 39111 Phone: 601-849-4070 Fax: 601-849-4055 |
 Dr. Jonathan W. Glenn, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 448 5th Ave Sw, Magee, MS 39111 Phone: 601-849-4070 Fax: 601-849-4055 |
 Dr. Criss Deann Loven, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 616 4th St Sw, Magee, MS 39111 Phone: 601-849-4070 Fax: 601-510-9714 |
News Archive
Favorable Austrian ruling for Ranbaxy on Atorvastatin
Ranbaxy Pharmaceuticals, Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (Ranbaxy), hasy announced that it successfully invalidated claims 1-3 (all claims sought to be invalidated) of Austrian Patent No. AT E 207 896 as anticipated by, and as lacking inventive step over, respectively, a Pfizer-owned published patent application and a Pfizer owned patent, as reflected by a decision released by the Austrian Patent Office.
A decade of neglect has weakened UNICEF and threatened the future of child survival
As a high-level forum assessing the progress on global health in relation to the millennium development goals concludes its meeting in Abuja, Nigeria, today, the rhetoric of success repeated by those charged with ending the needless deaths of millions of the world's children masks their own deep-seated failure to grapple with critical institutional weaknesses in their own ranks.
IDRI awarded $1.8M contract to develop adjuvant formulations for pandemic influenza
The Infectious Disease Research Institute has been awarded an $1.8 million contract from the Biomedical Advance Research and Development Authority. IDRI's work will focus on development of adjuvant formulations with options up to $8.5 million over three years when further development and manufacture of priority candidates are approved by the agency.
LEO Pharma enters into Asset Purchase Agreement to acquire Astellas' global dermatology business
LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.
› Verified 8 days ago
Physical Therapists
Optometrists
Speech-Language Pathologists
Chiropractors
Podiatrists
Occupational Therapists